PeDRA is a mission-driven research network dedicated to improving the lives of children with skin diseases through collaboration and discovery; to create, inspire, and sustain research to prevent, treat, and cure childhood skin disease.
A $65,000 grant to Phoenix Children’s Hospital for a patient-driven, physician-verified registry on congenital melanocytic nevi shows how Pediatric Dermatology Research Alliance Inc funds. The foundation backs pediatric dermatology research that is often collaborative, clinical, and built to generate evidence for future studies. Its recent awards include multi-center registries, phase 2 trials, and focused studies on childhood skin disease, with grants also reaching work on atopic dermatitis, hidradenitis suppurativa, acne, alopecia, vascular anomalies, and rare congenital skin conditions. The grant list suggests a research network that supports both early-stage investigation and more developed clinical projects. Awards go to universities, children’s hospitals, and medical centers, including a $40,000 grant to Children’s National Hospital for phenotyping hidradenitis suppurativa in pediatric patients and a $37,500 grant to Northwestern University for studying dupilumab, sleep, circadian function, and pruritus in children with moderate to severe atopic dermatitis. The largest recent grant in the file, $80,000 to the Medical College of Wisconsin, supported development of the Morphea Activity and Damage Measure, underscoring an emphasis on measurement tools and structured research infrastructure.
Several cause areas recur in the recent awards. In congenital and rare skin disease, the foundation gave $65,000 to Phoenix Children’s Hospital for a collaborative network and physician-verified registry on congenital melanocytic nevi, and $30,000 to Massachusetts General for non-invasive genomic testing of large and giant congenital nevi. In atopic dermatitis, it supported a $37,500 study at Northwestern University on dupilumab, sleep, circadian function, and pruritus, plus a $25,000 project at Icahn School of Medicine on predictive noninvasive biomarkers. The portfolio also reaches acne and adolescent care. Emory University received $25,000 for acne incidence and treatment in transgender adolescents, while the University of Colorado School of Medicine received $25,000 to develop an acne patient decision aid with and for Hispanic teenagers. Hidradenitis suppurativa appears as well, including a $40,000 award to Children’s National Hospital for phenotyping pediatric cases and a $10,000 Duke University grant on biologic drug survival.
$517K
$2M
$2.5M
$2.2M
Most grants fall between $20K and $28K, with a median of $25K.
25th Percentile
$20K
Median
$25K
75th Percentile
$28K
About 0% of grants go to recipients in CA.
MICHAEL SIEGEL
Top 2 recipient countries by grant volume for Pediatric Dermatology Research Alliance.
| Rank | Country | Grants | Total | Share |
|---|---|---|---|---|
| 1 | United StatesDomestic | 44 | $1.2M | 97.8% |
| 2 | Canada |
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Typical grant sizes cluster tightly: the 25th percentile is $20,000, the median is $25,000, and the 75th percentile is $27,500. The recent awards file shows a broad mix of $7,500 to $80,000 grants, with many awards at $20,000 or $25,000. The foundation’s grantmaking is largely project-based and research-oriented, with support going to studies, registries, trial design, and investigator development. The pattern also points to repeated funding in pediatric dermatology rather than isolated one-off philanthropy. The organization says its Grants & Fellowships Program has awarded more than $2.9 million since 2016, and its active programs include unsolicited pathways for certain grants and fellowships. It does not fund individuals and does not make program-related investments.
The grants are national, and every recipient in the recent list is in the United States. Arizona leads by grant count, driven by the Phoenix Children’s Hospital award. Other recurring recipient cities include Baltimore, Washington, DC, Evanston, and Boston, alongside grants in Philadelphia, Atlanta, Los Angeles, and San Francisco. No grants in the recent list go to Oregon recipients, despite the foundation’s Portland headquarters.
The recent grants focus on pediatric dermatology research across congenital nevi, atopic dermatitis, hidradenitis suppurativa, acne, alopecia, psoriasis, hemangioma monitoring, and skin disease measurement tools. Awards also support registries, clinical trials, cohort studies, and consensus or decision-aid development.
Typical awards cluster around $25,000. The grant-size distribution shows a 25th percentile of $20,000, a median of $25,000, and a 75th percentile of $27,500. The recent file also includes smaller $7,500 grants and a larger $80,000 grant.
Yes, for some programs. The PeDRA Grants & Fellowships Program and the Research Fellowships Program both accept unsolicited applications, and Study Support Grants also accept unsolicited applications. Several challenge grants and disease-specific collaborations do not.
Its scope is national, and the recent grants all go to U.S. recipients. The active programs also describe U.S.-only funding for several awards, while some programs extend to North America, including the U.S., Canada, and Mexico.
Recent grantees include universities, children’s hospitals, medical schools, and the National Institutes of Health. The awards support studies led by research and clinical institutions rather than individuals, consistent with the foundation’s stated policy of not funding individuals.
2026
Source: IRS Form 990-PF, fiscal year 2026.
| 1 |
| $20K |
2.2% |
Recipient country reflects the grantee's headquarters per IRS 990-PF and Schedule F filings, not the program's implementation country.
Current and upcoming funding from Pediatric Dermatology Research Alliance that your nonprofit may be able to apply for.
Who can apply: HCI proposals related to adolescent atopic dermatitis. Applicants should review the Call for Grant Applications, HCI Grant Submission Requirements, HCI Budget Template, and HCI Budget Components.
Deadline: Application deadline: September 30, 2026.
Who can apply: The principal investigator must be a PeDRA member; project must be accepted as a PeDRA Study (application via the PeDRA Study Application). Investigators can request support when submitting a Study Application; eligibility details are in the Study Application materials and PeDRA Grants & Fellowships Guidelines.
Deadline: Study applications are reviewed on a rolling basis; specific Study Support Grant deadlines or windows are provided to PeDRA Studies (see Grants & Fellowships Guidelines).
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| CHILDREN'S NATIONAL HOSPITAL | WASHINGTON, DC | $60,000 | 2026 | SPARC AA: SPATIAL PATTERNING ANALYSIS AND RELAPSE IN CHILDREN WITH ALOPECIA AREATA |
| PENN STATE AND HERSHEY MEDICAL CENTER | HERSHEY, PA | $53,940 | 2026 | THE EFFECT OF SYSTEMIC THERAPY ON STIGMA AND MENTAL HEALTH IN ADOLESCENT PATIENTS WITH HIDRADENITIS SUPPURATIVA: A PROSPECTIVE COHORT STUDY |
| CEDARS-SIANI MEDICAL CENTER | LOS ANGELES, CA | $50,000 | 2026 | EXPLORING THE PATHOGENESIS OF JUVENILE SYSTEMIC SCLEROSIS |
| JOHNS HOPKINS UNIVERSITY | BALTIMORE, MD | $40,000 | 2026 | ATOPIC DERMATITIS, SLEEP, AND COGNITIVE SKILLS IN EARLY CHILDHOOD |
| INDIANA UNIVERSITY | BLOOMINGTON, IN | $32,200 | 2026 | SHARED DECISION MAKING IN PROCEDURAL PEDIATRIC DERMATOLOGY RELATING TO NEOPLASM DIAGNOSIS AND MANAGEMENT |
| ICAHN SCHOOL OF MEDICINE | NEW YORK, NY | $29,000 | 2026 | CHARACTERIZING THE INFLAMMATORY SIGNATURE OF PEDIATRIC ATOPIC DERMATITIS AND CONCOMITANT ATOPIC DISEASES IN THAI PATIENTS |
| UNIVERSITY OF COLORADO | BOULDER, CO | $25,000 | 2026 | CHARACTERIZING DEFICITS IN EARLY-STAGE AUTOPHAGY AND LIPID ACCUMULATION IN IPSC-DERIVED FIBROBLASTS AND KERATINOCYTES FROM INDIVIDUALS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA |
| UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $25,000 | 2026 | CHILDHOOD ADVERSITY AND PEDIATRIC SKIN DISEASE: INVESTIGATING THE ROLE OF ADVERSE CHILDHOOD EXPERIENCES AND SOCIOECONOMICS |
| YALE UNIVERSITY | NEW HAVEN, CT | $25,000 | 2026 | LEVERAGING LARGE-SCALE ELECTRONIC HEALTH RECORDS AND PATIENT SURVEYS TO IDENTIFY COMORBIDITIES IN ICHTHYOSIS TO FACILITATE TRANSITION FROM PEDIATRIC TO ADULT CARE |
| EMORY UNIVERSITY | ATLANTA, GA | $25,000 | 2026 | ADOLESCENT ACNE EXPERIENCE AND MANAGEMENT IN ADOLESCENT-CAREGIVER DYADS |
| UNIVERSITY OF PENNSYLVANIA | PHILADELPHIA, PA | $25,000 | 2026 | IDENTIFYING RELIABLE MEASURES OF DISEASE ACTIVITY IN CRANIOFACIAL MORPHEA |
| CHILDREN'S HOSPITAL OF PHILADELPHIA | PHILADELPHIA, PA | $25,000 | 2026 | LEVERAGING ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY IN EPIDERMAL REPAIR (LADDER) |
| UNIVERSITY OF WISCONSIN | MADISON, WI | $20,000 | 2026 | AREA DEPRIVATION AND DISEASE SEVERITY IN PEDIATRIC PATIENTS WITH DLE AND SLE |
| UNIVERISTY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $20,000 | 2026 | DECIPHERING THE IMMUNOPATHOGENESIS OF REACTIVE INFECTIOUS MUCOCUTANEOUS ERUPTIONS |
| BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $20,000 | 2026 | 3D ENDOTHELIAL SPHEROID MODEL OF CAPILLARY MALFORMATIONS |
| THE HOSPITAL FOR SICK CHILDREN | TORONTO, ON | $19,669 | 2026 | QUANTITATIVE NANOHISTOLOGY PROFILING OF EXTRACELLULAR MATRIX ALTERATIONS IN PEDIATRIC STIFF SKIN SYNDROME AND EHLERSDANLOS SYNDROME |
| KENNEDY KRIEGER INSTITUTE | BALTIMORE, MD | $12,500 | 2026 | ADVANCING SCREENING AND EDUCATION FOR ECZEMA IN CHILDREN WITH NEURODEVELOPMENTAL AND COMPLEX MEDICAL NEEDS |
| VIRGINIA COMMONWEALTH UNIVERSITY | RICHMOND, VA | $10,000 | 2026 | CONSENSUS GUIDELINES FOR THE MANAGEMENT AND TREATMENT OF STAPH SCALDED SKIN SYNDROME IN CHILDREN |
| PHOENIX CHILDREN'S HOSPITAL | PHOENIX, AZ | $65,000 | 2025 | DEVELOPING A COLLABORATIVE NETWORK AND PATIENT DRIVEN PHYSICIAN VERIFIED REGISTRY FOR FURTHERING THE SCIENCE OF CONGENITAL MELANOCYTIC NEVI (CMN) AND IMPROVING PATIENT OUTCOMES |
| CHILDREN'S NATIONAL HOSPITAL | WASHINGTON, DC | $40,000 | 2025 | PHENOTYPING HIDRADENITIS SUPPURATIVA IN PEDIATRIC PATIENTS |
| NORTHWESTERN UNIVERSITY | EVANSTON, IL | $37,500 | 2025 | USING DUPILUMAB TO IMPROVE CIRCADIAN FUNCTION, SLEEP AND PRURITUS IN CHILDREN WITH MODERATE/SEVERE ATOPIC DERMATITIS |
| MASSACHUSETTS GENERAL | BOSTON, MA | $30,000 | 2025 | NON-INVASIVE GENOMIC TESTING OF LARGE AND GIANT CONGENITAL NEVI |
| EMORY UNIVERSITY | ATLANTA, GA | $25,000 | 2025 | ACNE INCIDENCE AND TREATMENT IN TRANSGENDER ADOLESCENTS: A MULTI-CENTER, VALIDATED COHORT STUDY |
| JOHNS HOPKINS UNIVERSITY | BALTIMORE, MD | $25,000 | 2025 | LONG-TERM MANAGEMENT OF SYSTEMIC TREATMENTS FOR PEDIATRIC ATOPIC DERMATITIS: A PILOT CLINICAL TRIAL AND MULTI-CENTER REGISTRY DEVELOPMENT |
| ICAHN SCHOOL OF MEDICINE | NEW YORK, NY | $25,000 | 2025 | DEFINING PREDICTIVE NONINVASIVE BIOMARKERS FOR PEDIATRIC ATOPIC DERMATITIS PATIENTS |
| UNIVERSITY OF COLORADO SCHOOL OF MEDICINE | AURORA, CO | $25,000 | 2025 | DEVELOPING AN ACNE PATIENT DECISION AID WITH AND FOR HISPANIC TEENAGERS |
| CINCINNATI CHILDREN'S HOSPITAL | CINCINNATI, OH | $10,000 | 2025 | CONSENSUS STATEMENT ON PULSED-DYE LASER TREATMENT FOR PORT-WINE BIRTHMARKS |
| DUKE UNIVERSITY | DURHAM, NC | $10,000 | 2025 | DRUG SURVIVAL OF BIOLOGICS IN PEDIATRIC PATIENTS WITH HIDRADENITIS SUPPURATIVA SEEN AT DUKE, MGH AND UMASS MEMORIAL HEALTH |
| NATIONAL INSTITUTES OF HEALTH | BETHESDA, MD | $7,500 | 2025 | INVESTIGATING THE PREVALENCE OF INBORN ERRORS OF IMMUNITY AND TREATMENT RESPONSES IN PEDIATRIC ALOPECIA AREATA: A MULTI-SITE STUDY |
| WASHINGTON UNIVERSITY IN ST LOUIS | STLOUIS, MO | $7,500 | 2025 | MAPPING THE CONGENITAL MELANOCYTIC NEVUS (CMN) REMOVAL JOURNEY: INSIGHTS FROM PATIENTS, FAMILIES, AND CLINICIANS |
| DARTMOUTH HITCHCOCK HEALTH | LEBANON, NH | $6,500 | 2025 | AN ANALYSIS OF LOCAL TREATMENT AVENUES FOR CUTANEOUS AND MUCOCUTANEOUS LEISHMANIASIS: A SYSTEMATIC REVIEW & META-ANALYSIS |
| THE MEDICAL COLLEGE OF WISCONSIN | MILWAUKEE, WI | $80,000 | 2024 | DEVELOPMENT OF THE MORPHEA ACTIVITY AND DAMAGE MEASURE (MADM) |
| STANFORD UNIVERSITY | STANFORD, CA | $60,000 | 2024 | A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE A TEMPORARY SKIN SUBSTITUTE |
| UNIVERSITY OF MISSISSIPPI | OXFORD, MS | $42,975 | 2024 | ELUCIDATING PSYCHOLOGICAL WELL-BEING AND ACCESS TO SUPPORT IN FAMILIES OF CH |
| JOHNS HOPKINS HOSPITAL | BALTIMORE, MD | $25,000 | 2024 | UNDERSTANDING PATIENT-REPORTED OUTCOMES IN PEDIATRIC PATIENTS RECEIVING SYST |
| CHILDREN'S NATIONAL HOSPITAL | WASHINGTON, DC | $25,000 | 2024 | SHARED JOURNEYS: A QUALITATIVE EXPLORATION OF PATIENT AND PARENT PERSPECTIVE |
| CHILDREN'S HOSPITAL OF PHILADELPHIA | PHILADELPHIA, PA | $25,000 | 2024 | GENETIC LANDSCAPE OF PEDIATRIC PATIENTS WITH MONOGENIC SUSCEPTIBILITIES TO |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | BRONX, NY | $25,000 | 2024 | NOVEL USE OF ORAL MINOXIDIL IN PEDIATRIC ALOPECIA PATIENTS |
| UNIVERSITY OF COLORADO | BOULDER, CO | $20,000 | 2024 | INVESTIGATING ACCESS TO PEDIATRIC DERMATOLOGY CARE FOR MINORITIZED YOUTH |
| UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $20,000 | 2024 | PEDIATRIC AUTOIMMUNE DISEASE: COMPREHENSIVE CHARACTERIZATION OF A RHEUMATOLO |
| HARVARD MEDICAL SCHOOL | BOSTON, MA | $20,000 | 2024 | QUALITY OF LIFE IN CHILDHOOD CANCER AND TRANSPLANT SURVIVORS WITH PERMANENT |
| NORTHWESTERN UNIVERSITY | EVANSTON, IL | $20,000 | 2024 | CARDIOVASCULAR RISK IN PEDIATRIC PSORIASIS |
| UNIVERSITY OF PENNSYLVANIA | PHILADELPHIA, PA | $20,000 | 2024 | THERMOGRAPHY TO MONITOR PROLIFERATION IN EVOLVING HEMANGIOMAS AT RISK FOR AG |
| UNIVERSITY OF CALIFORNIA LOS ANGELES | LOS ANGELES, CA | $20,000 | 2024 | BARRIERS TO CARE FOR PEDIATRIC ATOPIC DERMATITIS PATIENTS AND THE EFFECTS ON |
| MILTON S HERSHEY MEDICAL CENTER | HERSHEY, PA | $19,512 | 2024 | EXPERT RECOMMENDATIONS FOR USE OF HORMONAL THERAPIES IN PREADOLESCENT AND YO |
| VARIOUS GRANTS | — | $411,992 | 2023 | RESEARCH IN PEDIATRIC DERMATOLOGY FOR SCHOLARLY, CLINICAL OR BASIC RESEARCH. |
SPARC AA: SPATIAL PATTERNING ANALYSIS AND RELAPSE IN CHILDREN WITH ALOPECIA AREATA
THE EFFECT OF SYSTEMIC THERAPY ON STIGMA AND MENTAL HEALTH IN ADOLESCENT PATIENTS WITH HIDRADENITIS SUPPURATIVA: A PROSPECTIVE COHORT STUDY
EXPLORING THE PATHOGENESIS OF JUVENILE SYSTEMIC SCLEROSIS
ATOPIC DERMATITIS, SLEEP, AND COGNITIVE SKILLS IN EARLY CHILDHOOD
INDIANA UNIVERSITY
$32,200SHARED DECISION MAKING IN PROCEDURAL PEDIATRIC DERMATOLOGY RELATING TO NEOPLASM DIAGNOSIS AND MANAGEMENT
CHARACTERIZING THE INFLAMMATORY SIGNATURE OF PEDIATRIC ATOPIC DERMATITIS AND CONCOMITANT ATOPIC DISEASES IN THAI PATIENTS
UNIVERSITY OF COLORADO
$25,000CHARACTERIZING DEFICITS IN EARLY-STAGE AUTOPHAGY AND LIPID ACCUMULATION IN IPSC-DERIVED FIBROBLASTS AND KERATINOCYTES FROM INDIVIDUALS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$25,000CHILDHOOD ADVERSITY AND PEDIATRIC SKIN DISEASE: INVESTIGATING THE ROLE OF ADVERSE CHILDHOOD EXPERIENCES AND SOCIOECONOMICS
LEVERAGING LARGE-SCALE ELECTRONIC HEALTH RECORDS AND PATIENT SURVEYS TO IDENTIFY COMORBIDITIES IN ICHTHYOSIS TO FACILITATE TRANSITION FROM PEDIATRIC TO ADULT CARE
EMORY UNIVERSITY
$25,000ADOLESCENT ACNE EXPERIENCE AND MANAGEMENT IN ADOLESCENT-CAREGIVER DYADS
IDENTIFYING RELIABLE MEASURES OF DISEASE ACTIVITY IN CRANIOFACIAL MORPHEA
LEVERAGING ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY IN EPIDERMAL REPAIR (LADDER)
UNIVERSITY OF WISCONSIN
$20,000AREA DEPRIVATION AND DISEASE SEVERITY IN PEDIATRIC PATIENTS WITH DLE AND SLE
UNIVERISTY OF CALIFORNIA SAN DIEGO
$20,000DECIPHERING THE IMMUNOPATHOGENESIS OF REACTIVE INFECTIOUS MUCOCUTANEOUS ERUPTIONS
3D ENDOTHELIAL SPHEROID MODEL OF CAPILLARY MALFORMATIONS
THE HOSPITAL FOR SICK CHILDREN
$19,669QUANTITATIVE NANOHISTOLOGY PROFILING OF EXTRACELLULAR MATRIX ALTERATIONS IN PEDIATRIC STIFF SKIN SYNDROME AND EHLERSDANLOS SYNDROME
KENNEDY KRIEGER INSTITUTE
$12,500ADVANCING SCREENING AND EDUCATION FOR ECZEMA IN CHILDREN WITH NEURODEVELOPMENTAL AND COMPLEX MEDICAL NEEDS
VIRGINIA COMMONWEALTH UNIVERSITY
$10,000CONSENSUS GUIDELINES FOR THE MANAGEMENT AND TREATMENT OF STAPH SCALDED SKIN SYNDROME IN CHILDREN
DEVELOPING A COLLABORATIVE NETWORK AND PATIENT DRIVEN PHYSICIAN VERIFIED REGISTRY FOR FURTHERING THE SCIENCE OF CONGENITAL MELANOCYTIC NEVI (CMN) AND IMPROVING PATIENT OUTCOMES
PHENOTYPING HIDRADENITIS SUPPURATIVA IN PEDIATRIC PATIENTS
USING DUPILUMAB TO IMPROVE CIRCADIAN FUNCTION, SLEEP AND PRURITUS IN CHILDREN WITH MODERATE/SEVERE ATOPIC DERMATITIS
MASSACHUSETTS GENERAL
$30,000NON-INVASIVE GENOMIC TESTING OF LARGE AND GIANT CONGENITAL NEVI
EMORY UNIVERSITY
$25,000ACNE INCIDENCE AND TREATMENT IN TRANSGENDER ADOLESCENTS: A MULTI-CENTER, VALIDATED COHORT STUDY
LONG-TERM MANAGEMENT OF SYSTEMIC TREATMENTS FOR PEDIATRIC ATOPIC DERMATITIS: A PILOT CLINICAL TRIAL AND MULTI-CENTER REGISTRY DEVELOPMENT
DEFINING PREDICTIVE NONINVASIVE BIOMARKERS FOR PEDIATRIC ATOPIC DERMATITIS PATIENTS
UNIVERSITY OF COLORADO SCHOOL OF MEDICINE
$25,000DEVELOPING AN ACNE PATIENT DECISION AID WITH AND FOR HISPANIC TEENAGERS
CINCINNATI CHILDREN'S HOSPITAL
$10,000CONSENSUS STATEMENT ON PULSED-DYE LASER TREATMENT FOR PORT-WINE BIRTHMARKS
DRUG SURVIVAL OF BIOLOGICS IN PEDIATRIC PATIENTS WITH HIDRADENITIS SUPPURATIVA SEEN AT DUKE, MGH AND UMASS MEMORIAL HEALTH
NATIONAL INSTITUTES OF HEALTH
$7,500INVESTIGATING THE PREVALENCE OF INBORN ERRORS OF IMMUNITY AND TREATMENT RESPONSES IN PEDIATRIC ALOPECIA AREATA: A MULTI-SITE STUDY
MAPPING THE CONGENITAL MELANOCYTIC NEVUS (CMN) REMOVAL JOURNEY: INSIGHTS FROM PATIENTS, FAMILIES, AND CLINICIANS
AN ANALYSIS OF LOCAL TREATMENT AVENUES FOR CUTANEOUS AND MUCOCUTANEOUS LEISHMANIASIS: A SYSTEMATIC REVIEW & META-ANALYSIS
DEVELOPMENT OF THE MORPHEA ACTIVITY AND DAMAGE MEASURE (MADM)
A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE A TEMPORARY SKIN SUBSTITUTE
UNIVERSITY OF MISSISSIPPI
$42,975ELUCIDATING PSYCHOLOGICAL WELL-BEING AND ACCESS TO SUPPORT IN FAMILIES OF CH
JOHNS HOPKINS HOSPITAL
$25,000UNDERSTANDING PATIENT-REPORTED OUTCOMES IN PEDIATRIC PATIENTS RECEIVING SYST
SHARED JOURNEYS: A QUALITATIVE EXPLORATION OF PATIENT AND PARENT PERSPECTIVE
GENETIC LANDSCAPE OF PEDIATRIC PATIENTS WITH MONOGENIC SUSCEPTIBILITIES TO
NOVEL USE OF ORAL MINOXIDIL IN PEDIATRIC ALOPECIA PATIENTS
UNIVERSITY OF COLORADO
$20,000INVESTIGATING ACCESS TO PEDIATRIC DERMATOLOGY CARE FOR MINORITIZED YOUTH
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$20,000PEDIATRIC AUTOIMMUNE DISEASE: COMPREHENSIVE CHARACTERIZATION OF A RHEUMATOLO
QUALITY OF LIFE IN CHILDHOOD CANCER AND TRANSPLANT SURVIVORS WITH PERMANENT
THERMOGRAPHY TO MONITOR PROLIFERATION IN EVOLVING HEMANGIOMAS AT RISK FOR AG
UNIVERSITY OF CALIFORNIA LOS ANGELES
$20,000BARRIERS TO CARE FOR PEDIATRIC ATOPIC DERMATITIS PATIENTS AND THE EFFECTS ON
EXPERT RECOMMENDATIONS FOR USE OF HORMONAL THERAPIES IN PREADOLESCENT AND YO
VARIOUS GRANTS
$411,992RESEARCH IN PEDIATRIC DERMATOLOGY FOR SCHOLARLY, CLINICAL OR BASIC RESEARCH.
